

This article was downloaded by:

On: 26 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

KINETICS STUDY OF THE BIOTRANSFORMATION OF AN OLIGONUCLEOTIDE PRODRUG IN CELLS EXTRACT BY MATRIX-ASSISTED LASER DESORPTION/IONIZATION TIME-OF-FLIGHT MASS SPECTROMETRY

François Morvan^a; Jean-Charles Brès^a; Isabelle Lefebvre^a; Jean-Jacques Vasseur^a; Alain Pompon^a; Jean-Louis Imbach^a

^a Université Montpellier II, Montpellier, Cedex 5, France

Online publication date: 31 March 2001

To cite this Article Morvan, François , Brès, Jean-Charles , Lefebvre, Isabelle , Vasseur, Jean-Jacques , Pompon, Alain and Imbach, Jean-Louis(2001) 'KINETICS STUDY OF THE BIOTRANSFORMATION OF AN OLIGONUCLEOTIDE PRODRUG IN CELLS EXTRACT BY MATRIX-ASSISTED LASER DESORPTION/IONIZATION TIME-OF-FLIGHT MASS SPECTROMETRY', *Nucleosides, Nucleotides and Nucleic Acids*, 20: 4, 1159 – 1163

To link to this Article: DOI: 10.1081/NCN-100002510

URL: <http://dx.doi.org/10.1081/NCN-100002510>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

KINETICS STUDY OF THE BIOTRANSFORMATION OF AN OLIGONUCLEOTIDE PRODRUG IN CELLS EXTRACT BY MATRIX-ASSISTED LASER DESORPTION/IONIZATION TIME-OF-FLIGHT MASS SPECTROMETRY

François Morvan,* Jean-Charles Brès, Isabelle Lefebvre,
Jean-Jacques Vasseur, Alain Pompon, and Jean-Louis Imbach

Laboratoire de Chimie Organique Biomoléculaire de Synthèse,
UMR 5625 CNRS-UM II, Université Montpellier II, Place E. Bataillon,
34095 Montpellier Cedex 5, France

ABSTRACT

The fate of a dodecathymidine prodrug in cell extract was monitored by MALDI-TOF MS. This technique allows a facile identification and a relative quantification of metabolites produced. We showed that the relative peak intensities were similar to the relative metabolite proportions that permitted the determination of their half-lives. The oligonucleotide prodrug was fully metabolized to yield the T₁₂ phosphorothioate likely through a carboxyesterase mediated mechanism.

An oligonucleotide prodrug approach has been designed to overcome the hurdle of the poor uptake of oligonucleotides. Since the low uptake is due to the presence of negative charge on each phosphate (1) we decided to transitorily mask several of them with a carboxyesterase labile S-Acyl-2-ThioEthyl (SATE) group to gain more lipophilic oligos. We have shown that the resulting prooligos cross efficiently and rapidly the cellular membrane via a presumably passive mechanism and hence reach the nucleus (2,3). Since our strategy involves an

*Corresponding author.




Figure 1. Schematic structure of the prooligos **A** to **E**.

intracellular carboxyesterase activation to recover the unmasked oligonucleotide inside the cell, we studied the fate of these compounds in crude cell extract as a model of the intracellular medium. In this paper, we report the kinetics study of the demasking of a MeSATE T₁₂ prooligo **A** (Fig. 1) in cell extract monitored by MALDI-TOF MS without any sample pretreatment except drop dialysis to remove salts (4).

We studied the kinetics and the decomposition pathway of the prooligo **A** bearing nine thionophosphotriester MeSATE groups and four charged thionophosphodiester (Fig. 1). The hydrolysis of the prooligo **A** should yield the nuclease resistant T₁₂p phosphorothioate (PS-T₁₂p) and the expected metabolites should be the prooligo **A** being lost one to nine MeSATE groups. Furthermore as cell extract displays also phosphatase activities the 3'-end phosphorothioate will be hydrolyzed to yield the parent phosphorothioate dodecathymidine (PS-T₁₂).

We also studied the demasking kinetics of the four other related prooligos with respectively eight (**B**), six (**C**), four (**D**) and two (**E**) MeSATE groups (Fig. 1) to obtained more accurate half-life on the last metabolites. Each prooligo **B** to **E** is a possible metabolite of **A**. Thus we assumed that they are representative compounds of the prooligo population bearing the same number of MeSATE groups. Each prooligo was synthesized on solid support as already described in reference (5) using the both phosphoramidite and H-phosphonate chemistries. Then to study the kinetics of hydrolysis, each prooligo (**A** to **E**) was incubated at 37°C at a 10 μM concentration in CEM SS cell extract. After a predetermined time, 5 μl of the resulting mixture was taken up and desalted by dialysis on a nitrocellulose membrane (Millipore) floating on a 0.1 M ammonium citrate solution for 30 min to remove salts (Na⁺, K⁺) able to form multiple adducts that will compromise the mass analysis. Then 1 μl was mixed with 10 μl of 2,4,6-trihydroxyacetophenone (THAP) matrix and 1 μl was loaded on the MALDI target to crystallize and subjected to MALDI-TOF MS analysis. Time-dependent mass spectra of prooligo **A** and its metabolites produced after incubation in cell extract is shown in Figure 2. It was easy to assign the attribution of each peak which were spaced out of 102 u corresponding to the loss of one MeSATE group (C₄H₆OS 102.2). Finally, the MALDI-TOF spectrum






Figure 2. Time dependent MALDI-TOF mass spectra of prooligo A incubated in cell extract.




Figure 3. Kinetics curves of prooligos A.



obtained after 24 h incubation shows that the parent PS-T₁₂ fully unmasked was reached and then was slowly degraded by a 3'-exonuclease activity which corresponds to a loss of a 5'-monophosphorothioate thymidine (C₁₀H₁₃N₂O₆PS, 320.3) (Fig. 2).

From each MALDI spectrum, the height of each signal was measured and converted in relative proportion, assuming that each metabolite flew in a similar extent than the others. This hypothesis was done since the formed metabolites exhibit a similar structure (all T₁₂). That allows a relative quantification of each metabolite. Quantification of oligonucleotides remains largely unexplored (6) and at our knowledge this is the first time that a relative quantification of oligonucleotide metabolites in a biological medium by MALDI-TOF MS is reported. For the five kinetics studies, the relative proportion were treated according to a consecutive pseudo-first order kinetic model (7) and we found that experimental points of each analyte fit well with its calculated curve which substantiates the reliability of the method. These data suggests that the hydrolysis of MeSATE group proceeded according to a mechanism of pseudo-first order and confirms our hypothesis that each analyte displays similar desorption ionization properties. The half-lives were determined from the five kinetics. It appeared that the substrate capacity of prooligo for the carboxyesterases increased when the number of MeSATE group decreased (t_{1/2} = 62 to 24 min).

In conclusion this method allows to visualize all the metabolites formed which correspond to the population of the prooligo being lost one to nine MeSATE groups and the 3'-end phosphorothioate monoester T₁₂. This method required only few material (0.25 OD_{260nm}, 2.5 nmol), was rapid and did not necessitate a sample preparation except a drop dialysis. It was possible to determine the half-life of each metabolite from the data obtained on MALDI-TOMS spectra by means of a relative quantification. Finally, we showed that the expected oligonucleotide parent PS-T₁₂ was obtained likely by means of a carboxyesterase mediated mechanism.

			<u>A</u>	<u>B</u>	<u>C</u>	<u>D</u>	<u>E</u>	Average
H	1	T12p+9MeSATE	62*					62
A	2	T12p+8MeSATE	49	50*				49
L	3	T12p+7MeSATE	44	37				44 ± 4
F	4	T12p+6MeSATE	35	33	26*			34 ± 1
–	5	T12p+5MeSATE	33	30	25			32 ± 2
L	6	T12p+4MeSATE	29	26	28	15*		28 ± 2
I	7	T12p+3MeSATE		24	28	15		28 ± 2
F	8	T12p+2MeSATE			27	16	14*	22 ± 6
E	9	T12p+1MeSATE			30	22	19	24 ± 5
(min)	10	T12p				28	23	26 ^[a] ± 3
	11	T 12				356	271	314 ^[b] ± 43

^[a]3'-phosphatase activity, ^[b]3'-exonuclease activity, *Correspond to an unique substrate.

ACKNOWLEDGMENTS

This work was supported by grants from "Association pour la Recherche contre le Cancer" (ARC) and the "Comités de l'Aude et des Pyrénées Orientales de la Ligue contre le Cancer". JCB thanks the "ADER" for the award of a research studentship. We thank Dr. A.-M. Aubertin for the gift of the cell extract.

REFERENCES

1. Shoji, Y.; Akhtar, S.; Periasamy, A.; Herman, B.; Juliano, R.L. *Nucleic Acids Res.* **1991**, *19*, 5543–5550.
2. Vivès, E.; Dell'Aquila, C.; Bologna, J.C.; Morvan, F.; Rayner, B.; Imbach, J.L. *Nucleic Acids Res* **1999**, *27*, 4071–4076.
3. Morvan, F.; Vasseur, J.-J.; Vivès, E.; Rayner, B.; Imbach, J.-L. (2000) In *Pharmaceutical aspects of oligonucleotides* (P. Couvreur and C. Malvy, Eds.), Chap. 3, pp. 79–97. Taylor & Francis, London.
4. Marusyk, R.; Sergeant, A. *Anal. Biochem.* **1980**, *105*, 403–404.
5. Bologna, J.C.; Morvan, F.; Imbach, J.L. *Eur. J. Org. Chem.* **1999**, 2353–2358.
6. Bruenner, B.A.; Yip, T.T.; Hutchens, T.W. *Rapid Comm. Mass Spectrom.* **1996**, *10*, 1797–1801.
7. Valette, G.; Pompon, A.; Girardet, J.L.; Cappellacci, L.; Franchetti, P.; Grifantini, M.; Lacolla, P.; Loi, A.G.; Perigaud, C.; Gosselin, G.; Imbach, J.L. *J. Med. Chem.* **1996**, *39*, 1981–1990.



Request Permission or Order Reprints Instantly!

Interested in copying and sharing this article? In most cases, U.S. Copyright Law requires that you get permission from the article's rightsholder before using copyrighted content.

All information and materials found in this article, including but not limited to text, trademarks, patents, logos, graphics and images (the "Materials"), are the copyrighted works and other forms of intellectual property of Marcel Dekker, Inc., or its licensors. All rights not expressly granted are reserved.

Get permission to lawfully reproduce and distribute the Materials or order reprints quickly and painlessly. Simply click on the "Request Permission/Reprints Here" link below and follow the instructions. Visit the [U.S. Copyright Office](#) for information on Fair Use limitations of U.S. copyright law. Please refer to The Association of American Publishers' (AAP) website for guidelines on [Fair Use in the Classroom](#).

The Materials are for your personal use only and cannot be reformatted, reposted, resold or distributed by electronic means or otherwise without permission from Marcel Dekker, Inc. Marcel Dekker, Inc. grants you the limited right to display the Materials only on your personal computer or personal wireless device, and to copy and download single copies of such Materials provided that any copyright, trademark or other notice appearing on such Materials is also retained by, displayed, copied or downloaded as part of the Materials and is not removed or obscured, and provided you do not edit, modify, alter or enhance the Materials. Please refer to our [Website User Agreement](#) for more details.

[Order now!](#)

Reprints of this article can also be ordered at

<http://www.dekker.com/servlet/product/DOI/101081NCN100002510>